Bionano OGM studies at ESHG 2026 surge 67% year-on-year

Bionano Genomics reported that 35 studies featuring its optical genome mapping (OGM) technology were presented at the 2026 European Society of Human Genetics conference, a 67% increase on the 21 studies that appeared at the same event in 2025. Authorship spanned 17 countries, up from 12, covering research groups across Europe, North America, South America, Asia and the Middle East.

The breadth of application areas was notable. Rare and constitutional genetic disorders accounted for roughly half of the studies, with the remainder spread across haematologic malignancies, solid tumours, hereditary cancer, reproductive health and cardiovascular genomics. Europe contributed the largest share of studies overall, while Brazil emerged as the single largest national contributor, with several groups from the University of São Paulo and the University of Brasília among the presenting authors.

Expanding the structural variant toolkit

A recurring theme across the presentations was OGM's ability to detect complex structural variants that remain invisible or ambiguous under standard cytogenetic approaches such as chromosomal microarray and classical karyotyping. Several studies paired OGM with long-read sequencing, positioning the two technologies as complementary rather than competing. A proof-of-concept study from Medicover Genetics in Germany directly compared OGM against long-read sequencing for structural variant discovery, and work from Vancouver General Hospital assessed the combined platform for rapid methylation and copy number profiling in gliomas.

Alka Chaubey, chief medical officer of Bionano, said the ESHG presentations demonstrated OGM's capacity to "resolve complex genomic rearrangements, identify cryptic structural variants, and provide insights that may not be accessible through traditional cytogenetic and sequencing approaches."

Market context and competitive landscape

The growth in OGM-related publications at ESHG is a meaningful indicator of academic and translational interest, though Bionano faces a more complex commercial backdrop. The company has disclosed going-concern uncertainties in filings with the US Securities and Exchange Commission and has stated that it requires additional financing to fund its strategic plans. That financial pressure is relevant context for interpreting conference momentum, which does not translate automatically into laboratory procurement decisions.

In the structural variant detection space, OGM competes with a cluster of long-read sequencing platforms from Pacific Biosciences and Oxford Nanopore Technologies, both of which are actively expanding their clinical and research positioning. Short-read whole-genome sequencing, meanwhile, continues to decline in cost, keeping it in contention for many routine applications. The comparative studies appearing at ESHG 2026 suggest that laboratory scientists are actively benchmarking these approaches, which is a prerequisite for broader clinical adoption but also a sign that the technology landscape has not yet settled.

Bionano noted that all its products are currently approved for research use only and are not cleared for use in diagnostic procedures, a regulatory distinction that limits near-term revenue capture from clinical laboratories even as scientific interest grows. A transition toward diagnostic clearance in one or more jurisdictions would represent a material commercial milestone for the company.